EDITORIAL PROCESS

Following is an outline describing the editorial process for Molecular Medicine.

Criteria
The mission of Molecular Medicine is to publish recent original findings that elucidate the pathogenesis of disease at the molecular or physiological level, which may lead to the design of specific tools for disease  diagnosis, treatment, or prevention. Manuscripts containing original material relevant to the genetic, molecular,  or cellular basis of key physiologic or disease processes are considered for publication if neither the article nor  any part of its essential substance, tables, or figures has been or will be published or submitted elsewhere before appearing in Molecular Medicine. Manuscripts published in Molecular Medicine should contain human or animal in vivo or ex vivo data and describe the implications of the results for human disease and medicine, at a level approachable by our broad audience.

Publication Decisions
Molecular Medicine's Editors, not its reviewers, judge which submissions will appeal to our broad audience. Reviewers contribute constructive reports and comments, and suggest preliminary decisions. Publication is  informed by prominence, significance, and timeliness of the findings, as well as general appeal of the work to a broad audience.

Pre-submission Enquiries
Please see: http://www.molmed.org/author_center.html

Cover Letter
Please see: http://www.molmed.org/author_center.html

Peer-Review
Once submitted, a manuscript will be reviewed by the Editors who consider whether to send the work for peer-review. The manuscript deemed suitable for the journal will be assigned to an Editor who has agreed to undertake its rapid review, soliciting the opinions of independent reviewers. While authors are required to submit three potential reviewers, Editors are free to decide whom to invite for a review. Editors normally honor requests that a manuscript not be sent to competing groups for review. Most manuscripts receive two or three reviews, however, some receive more, and occasionally some receive just one. Reviewers are chosen based on their independence from the authors, ability to evaluate technical aspects of the paper fairly, availability to return a review within the required timeframe, and quality of previous reviews (if applicable). Reviewers report on: whether the manuscript contributes to our understanding of disease pathogenesis; whether the work includes a molecular tool for disease diagnosis, treatment or prevention; what audience the work will appeal to and why; and any technical issues that may need to be addressed. Reviewers then make a recommendation on whether to accept, defer a decision, or reject the work. For instructions for reviewers please see: http://www.molmed.org/info_reviewers.pdf

Decisions
Once a manuscript has undergone a round of review, authors will receive one of the following decisions:

• Accept – the manuscript is accepted for publication, no further changes required;
  
• Accept, Minor – the manuscript is accepted for publication in principle, once the authors have made revisions requested by reviewers;
  
• Decision Deferred – a final decision on publication is deferred, pending the authors' response to the reviewers' comments;
  
• Reject, No Hope – the paper is rejected with no offer to reconsider a resubmitted version.

Open Access
Molecular Medicine is an open access publication. All content is published free online, ahead of print, on the Web site www.molmed.org within an average of 8 days after acceptance. These documents are marked "uncorrected proof" and will be replaced at a later date with final author-approved PDFs. Papers are also posted rapidly to PubMed with an e-publication ahead of print citation. Work will automatically be submitted to PubMed Central according to the NIH Public Access Policy. Following author approval, final PDFs will be submitted to the National Library of Medicine. Molecular Medicine does not embargo content.

This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

Production
After acceptance, the production staff copyedits the manuscript. This ensures the work conforms to Molecular Medicine's house style and that figures and tables are of publication quality, clarity and size. Authors will then receive a proof, which may include queries to be addressed. The corresponding author is responsible for completing this work with the production staff. The corresponding author is responsible for the accuracy of content, spelling of names and affiliations of all co-authors.

Publication
Final author-approved PDF papers will be posted to PubMed and PubMed Central on a rolling basis. At the culmination of each calendar month, PDFs posted during that month will be bundled into an issue. Molecular Medicine does not fulfill individual or institutional subscriptions from the Editorial Office. Users wishing to purchase a single issue, a special  issue, a back issue, an annual subscription, offprints, reprints, or individual copies of a manuscript will be directed to our print-on-demand website (currently in development with an anticipated launch in the first quarter of 2012). For questions, please contact subscriptions@molmed.org.

Appeals
Molecular Medicine's Editors are unable to assign high priority to consideration of appeals. The appeals process is time intensive and Molecular Medicine's Editors may be delayed in responding while reviewing individual cases. Manuscripts must not be submitted for publication elsewhere during this time. Appeals must be made in writing (editor@molmed.org) and should be restricted to the scientific case for publication.

Contact Information
Molecular Medicine
The Feinstein Institute for Medical Research
350 Community Drive, Manhasset, NY 11030
Website: www.molmed.org
Email: editor@molmed.org
Phone: 516 562-2114
Fax: 516 562-1022

EDITORS IN CHIEF

Kevin J Tracey, MD
The Feinstein Institute for Medical Research
Manhasset, NY, USA
Email

Anthony Cerami, PhD
Kenneth S Warren Laboratories
Tarrytown, NY, USA
Email

EDITORIAL STAFF

Michael Bukrinsky, MD, PhD
George Washington University
Washington DC, USA

Nicholas Chiorazzi, MD
The Feinstein Institute for Medical Research
Manhasset, NY, USA

Robert J Desnick, MD, PhD
Mount Sinai School of Medicine
New York, NY, USA

Betty Diamond, MD
The Feinstein Institute for Medical Research
Manhasset, NY, USA

Charles A Dinarello, MD
University of Colorado Health Sciences
Denver, CO, USA

Hannelore Ehrenreich, MD
Max-Planck Institute for
Experimental Medicine
Goettingen, Germany

Bruce Furie, MD
Harvard Medical School
Boston, MA, USA

Paul Greengard, PhD
Rockefeller University
New York, NY, USA

Peter K Gregersen, MD
The Feinstein Institute for Medical Research
Manhasset, NY, USA

Leonard C Harrison, MD, DSc
The Walter and Eliza Hall Institute of
Medical Research
Royal Melbourne Hospital
Victoria, Australia

Lars Klareskog, MD, PhD
Karolinska Institute
Stockholm, Sweden

Diane Mathis, PhD
Joslin Diabetes Center
Boston, MA, USA

Salvador Moncada, MD, FRS
The Wolfson Institute for Biomedical Research
University College London
London, UK

Carl F Nathan, MD
Cornell University
New York, NY, USA

Laurie Glimcher, MD
Harvard University
Boston, MA, USA

Bert W O'Malley, MD
Baylor College of Medicine
Houston, TX, USA

Athanasios G Papavassiliou, MD, PhD
Medical School, University of Athens
Athens, Greece

Arthur B Pardee, PhD
Dana Farber Cancer Institute
Boston, MA, USA

Stanley Prusiner, MD
University of California, San Francisco
San Francisco, CA, USA

Marc H Symons, PhD
The Feinstein Institute for Medical Research
Manhasset, NY, USA

Emil R Unanue, MD
Washington University School of Medicine
St. Louis, MO, USA

Denisa Wagner, PhD
Harvard Medical School
Boston, MA, USA

Stephen Weiss, MD
University of Michigan, Ann Arbor
Ann Arbor, MI, USA